A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
for Neuroblastoma Recurrent
4 locations incl. San Francisco
Sponsor: St. Jude Children's Research Hospital
Sex: All·Age: Up to 30
Code: NCT07085338·Phase 2·Recruiting